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Abstract
Pregnancy and birth cohorts have been utilised extensively to investigate the developmental origins of health and disease, particularly in relation to under-
standing the aetiology of obesity and related cardiometabolic disorders. Birth and pregnancy cohorts have been utilised extensively to investigate this area of
research. The aim of the present review was twofold: ﬁrst to outline the necessity of measuring cardiometabolic risk in children; and second to outline how
it can be assessed. The major outcomes thought to have an important developmental component are CVD, insulin resistance and related metabolic out-
comes. Conditions such as the metabolic syndrome, type 2 diabetes and CHD all tend to have peak prevalence in middle-aged and older individuals but
assessments of cardiometabolic risk in childhood and adolescence are important to deﬁne early causal factors and characterise preventive measures.
Typically, researchers investigating prospective cohort studies have relied on the thesis that cardiovascular risk factors, such as dyslipidaemia, hypertension
and obesity, track from childhood into adult life. The present review summarises some of the evidence that these factors, when measured in childhood, may
be of value in assessing the risk of adult cardiometabolic disease, and as such proceeds to describe some of the methods for assessing cardiometabolic risk
in children.
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Why is assessing cardiovascular risk in childhood important
for developmental origins research?
A geographical correlation between infant and later CVD mor-
tality provided some of the ﬁrst evidence that adverse condi-
tions during development could have latent and long-term
effects on diseases that were previously considered to have
their origins during adulthood(1). Following earlier speculation
that this may reﬂect maternal/infant nutrition at critical stages
of development, David Barker’s team went on to report evi-
dence that lower birth weight was an independent risk factor
for later CHD and the metabolic syndrome. In this context,
low birth weight represents a tangible, albeit multifactorial,
reﬂection of a suboptimal in utero environment. The resulting
developmental origins of health and disease (DOHaD) para-
digm proposed that a range of metabolic, immunological
and physiological adaptations to suboptimal antenatal
Abbreviations: DOHaD, developmental origins of health and disease; DXA, dual-energy X-ray absorptiometry; IMT, intima media thickness; NAFLD, non-alcoholic fatty
liver disease; PWV, pulse wave velocity; TNFR, TNF receptor.
*Corresponding author: Dr Rae-Chi Huang, email rae-chi.huang@uwa.edu.au
© The Author(s) 2015. The online version of this article is published within an Open Access environment subject to the conditions of the Creative
Commons Attribution license <http://creativecommons.org/licenses/by/3.0/>.
JNS
JOURNAL OF NUTRITIONAL SCIENCE
1
conditions acts in concert with postnatal conditions to modify
subsequent disease risk (Fig. 1)(2).
The quality of the in utero environment is inﬂuenced by
broad-ranging maternal environmental factors, maternal gen-
eral health and ﬁxed genetic variability. Experimentally, mater-
nal environmental inﬂuences which have been studied include
nutritional status (in the periconceptional period(3,4) and dur-
ing pregnancy(5,6)), physical activity, pharmacological agents
(prescribed and illicit), patterns of microbial diversity, smoking
and pollutants. Some of these have been shown to have epi-
genetic effects on diverse aspects of fetal development. A simi-
lar set of inﬂuences operates, variably, in the postnatal
environment, also interacting with the genetic and epigenetic
processes to affect developmental processes. Within the
schema shown in Fig. 1 cardiometabolic risk is important as
both an outcome measure and as a mediator/predictor of
future health and well-being.
The growing global burden of obesity is now affecting all
regions of the world, and associated cardiometabolic disorders
are among the greatest threats to human health. To address
this public health crisis, it is important to understand why
obesity has developed so rapidly in such a short space of
time. Obese women and those who develop gestational dia-
betes are more likely to have offspring who themselves are
obese(7) and have an increased risk of metabolic disease(8,9).
This suggests that early life effects (potentially through obesity
and hyperglycaemia during pregnancy) could be an important
factor in the rising obesity rates being observed worldwide.
Studies of short-lived animals, which can be readily under-
taken across the entire lifespan (from before conception to the
disease end point of interest), have consistently provided
support for the DOHaD concept. This is far more challenging
in human studies which require long-term longitudinal follow-
up. There are further differences between animal and human
studies. Most of the animal models rely on controlled nutritional
interventions(10,11) which have provided strong evidence of a
causal relationship between early-life exposure and metabolic
risk in later life. Early-life exposures in humans are much
more complex and multifactorial, with exposures such as smok-
ing, drug exposure, stress and toxins at play. Despite these lim-
itations, it is critical that the observed effects on fetal
programming are replicated in human studies. Further, it is
important to rigorously ascertain whether interventions aimed
at favourably altering fetal programming are effective in humans.
Human DOHaD research has been conducted in many pro-
spective mother–offspring cohorts and in a broad range of
early-life intervention studies. Most current prospective popu-
lation studies(12–14) and almost all intervention studies(15–18)
involve offspring who have not yet reached old age, or even
middle age. As a consequence, they often do not as yet have
deﬁnitive CVD endpoints (such as CHD and stroke). So far,
the reported outcomes from these prospective human studies
are less deﬁnitive ‘risk’-associated parameters measured from
childhood, adolescence or young adult life (see below).
These prospective mother–offspring studies per se will not be
able to establish direct cause-and-effect relationships between
speciﬁc exposures and clinical outcomes. Nevertheless they (in
combination with animal models and human randomised con-
trolled trials) will play a key role in building the overall picture
of the role of DOHaD in human populations.
The utility of cardiovascular risk markers depends on evi-
dence that these ‘track’ from adolescent/childhood through
Fig. 1. Purported pathways involved in developmental origins of health and disease concepts. Cardiometabolic risk can be both an outcome and also a mediator
towards ultimate CVD.
2
journals.cambridge.org/jns
to adult life and, by extrapolation, that those with elevated risk
measures earlier in life are also more likely to suffer CVD later
in life(19–23). Speciﬁcally, many studies demonstrate that a spec-
trum of cardiovascular risk factors including hypertension(19),
dyslipidaemia(20), obesity(21) and the metabolic syndrome(22,23)
track from childhood into adulthood. For example, in the
Bogalusa Heart Study, twice the expected number of subjects
whose blood pressure levels were in the highest quintile of
blood pressure in childhood remained in the highest part of
the distribution 15 years later(19). Similarly, overweight 2- to
5-year-olds in the Bogalusa study were more than four times
more likely to become overweight adults, compared with chil-
dren classiﬁed with BMI less than the 50th centile(21). In the
Fels study, a child or adolescent with a high BMI percentile
for age remained at high risk of being overweight or obese
at 35 years of age. Interestingly, this risk increased in magni-
tude with increasing age(24). A systematic review has shown
that all included studies consistently report an increased risk
of overweight and obese youth becoming overweight
adults(25).
Several key postnatal factors, in particular postnatal weight
gain, have been shown to predict cardiovascular risk, inde-
pendent of birth size(26) and early childhood obesity may be
on the pathway between early-life factors and cardiovascular
outcomes. As such, childhood obesity and insulin resistance
can be utilised as both determinants of cardiovascular risk
and/or as outcomes in epidemiological models. Clearly,
childhood obesity is a major health issue in its own right
with a broad range of immediate health risks, in addition to
the long-term risk of CVD and many non-communicable
diseases(27).
Assessing obesity and adiposity in children
Alongside the virtually universal measures of BMI, prospective
cohort studies often include other anthropometric measures
including waist circumference, skinfold thicknesses, and some-
times measurements of body composition from DOHaD
(dual-energy X-ray absorptiometry; DXA) and bioimpedance
methodologies.
Other methods of assessing adiposity in childhood
In infants and children BMI is generally a less predictive meas-
ure of overall adiposity than in adults, and methods for asses-
sing adiposity in cohort studies have recently been
reviewed(28). More reﬁned methods of measuring adiposity
and body composition in childhood may have utility in dissect-
ing the role of the contribution of DOHaD mechanisms to
ultimate cardiovascular risk. A long-recognised and consistent
ﬁnding is that low birth weight followed by postnatal weight
gain is associated with a central distribution of adiposity,
increased percentage of body fat and increased skin
folds(29,30). High birth weight is also associated with later obes-
ity risk. This suggests that both impaired and excessive growth
in utero have effects on programming for obesity. Therefore,
measuring body composition may provide greater sensitivity
to understanding the early programming of obesity. The
most commonly used of these techniques include DXA(31),
bioelectrical impedance(32), air displacement plethysmography,
MRI and magnetic resonance spectroscopy (MRS). There is
emerging evidence that ectopic fat deposits such as in the
renal sinus, myocardial region and peripancreatic regions are
best quantiﬁed using MRI(33). Bioelectric impedance is port-
able and relatively inexpensive, but not as accurate as DXA
or MRI. Bioelectric impedance is particularly prone to inaccur-
acies with changes in body water:adipose ratio, as could occur
with illness and dehydration(32). When employing techniques
such as MRI, MRS and DXA in large-scale longitudinal stud-
ies, considerations of cost and time commitment to the parti-
cipants are necessary, particularly if these measurements are to
be repeated at several follow-ups. DXA cannot distinguish
between visceral and subcutaneous fat.
Cross-sectional assessment of anthropometric measures
In the literature on adults, there has been much debate about
the anthropometric measures that best predict cardiovascular
risk in cross-sectional and longitudinal studies. It is generally
agreed that measures of central adiposity and abdominal vis-
ceral fat deposition, such as waist:hip ratio and waist circum-
ference(34), are likely to be superior to BMI, at least in adults.
However, the role of these measures in childhood is less
deﬁnitive. Rather, there is some evidence that measures of
central obesity in children are not more predictive of cardio-
metabolic risk than BMI Z score(35,36). In contrast to adults,
waist:hip ratio in children does not predict blood lipids,
blood pressure and traditional cardiovascular risk factors.
However, there are some metabolic risk markers, namely fast-
ing TAG and homeostatic model assessment of insulin resist-
ance (HOMA-IR), that do appear to be associated with
anthropometric measures such as BMI or waist circumfer-
ence(30). Furthermore, cholesterol and LDL are inversely asso-
ciated with height. In childhood, there may be no ‘best’
cross-sectional measure of cardiovascular risk, and the choice
of optimal cross-sectional anthropometric measure should
depend on the research question being asked.
Longitudinal assessment of anthropometric measures
Fortunately most birth cohorts have repeat measures of
anthropometry which provide the opportunity for longitudinal
statistical modelling to be applied to obesity measures.
Longitudinal measures may have more value than cross-
sectional measures in answering DOHaD-related questions.
The present review is not intended as a comprehensive review
of statistical longitudinal methods or of relative efﬁciencies of
each method, but considers how these measures may be most
relevant to investigating DOHaD phenomena. Sufﬁce to say,
there are many techniques for investigating longitudinal mea-
sures including linear mixed-effects model, linear
mixed-effects model with skew-t random errors, semi-
parametric linear mixed models, latent class models and non-
linear mixed-effects modelling. Careful selection of the most
appropriate statistical tool to answer each different life-course
question is critical.
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Pathways to childhood obesity are likely to be heteroge-
neous, and under the inﬂuence of a number of maternal and
childhood factors acting at different time points (Fig. 1).
Longitudinal statistical techniques, particularly those that iden-
tify different patterns of growth are useful(37–39) particularly as
they assume and identify different, and potentially causal, path-
ways to obesity. For example, there is evidence that childhood
obesity can occur through DOHaD effects related to
large-for-gestational-age neonates who are exposed to the in
utero effects of gestational diabetes and maternal obesity(9).
By contrast, childhood obesity can also be driven by starvation
in utero as occurred to fetuses exposed during the Dutch
Hunger Winter(40).
Assessing cardiometabolic risk in children
Obesity does not usually occur in isolation, but generally
occurs within a cluster of abnormalities that includes hyperten-
sion, dyslipidaemia and insulin resistance. There are some
points to note, speciﬁc to children, when interpreting these
individual risk factors. Z scores of blood pressure speciﬁc
for age, sex and height of the child are most appropriate for
evaluation of high blood pressure in childhood(41). Likewise,
age, sex and puberty all affect fasting total cholesterol, LDL,
HDL, TAG and insulin levels through childhood(42).
The co-occurrence of these risk factors, ‘Syndrome X’, is a
phenomenon identiﬁed by Reaven in 1988, and subsequently
recognised by various different names, most commonly now
as the metabolic syndrome(43). Deﬁning the metabolic syn-
drome in children is problematic. In adults, the deﬁnition is
based upon arbitrary cut-offs with three main consensus deﬁ-
nitions (National Cholesterol Education Program (NCEP),
WHO and the International Diabetes Federation
(IDF))(44,45). Consensus deﬁnitions all vary slightly in terms
of the cut-off limits used, and it is important to emphasise
that these apply a bimodal approach to risk factors that gener-
ally have continuous relationships with disease across the
range. They also vary with ethnicity, and adult deﬁnitions are
not appropriate to translate to studies of children. At present,
in children, there is no consensus around deﬁnitions of the
metabolic syndrome. As an illustration of this controversy,
in 2008, in excess of forty unique paediatric deﬁnitions of
the metabolic syndrome in children had been used in the litera-
ture(46). Two of the more recent major deﬁnitions were com-
pared with different groups being identiﬁed in the same
population. The IDF metabolic syndrome criterion represents
a more stringent deﬁnition that was adapted from the NCEP
deﬁnition(47).
To overcome some of these issues of deﬁnition in children,
one approach is to use ‘data-driven’ methods to avoid use of
arbitrary cut-offs. This involves methods that can identify nat-
ural groupings within a population. For example, cluster ana-
lysis is a data-driven method that identiﬁes groups
maximising within-group similarities and maximising
between-group differences using a variety of statistical
algorithms(48).
This approach was used in the West Australian Pregnancy
Cohort (Raine) Study. Speciﬁcally, cluster analysis was
undertaken using continuous variables (BMI, systolic blood
pressure, fasting serum TAG and HOMA-IR) to identify a
group of children with features similar to the metabolic syn-
drome. At ages 8, 14 and 17 years, 29%(14), 24%(49) and
19% of the population, respectively, were identiﬁed as in the
‘high metabolic risk’ cluster. These groups were highly diver-
gent for traditional risk factors (Fig. 2), and included a sub-
stantially larger proportion of the population than would
have been deﬁned by conventional deﬁnitions. This gives
greater power to analyse associations with these metabolic
cluster groups, as compared with groups deﬁned using meta-
bolic syndrome deﬁnitions. Utilising this cluster technique, the
U-shaped relationship with birth weight was shown in a con-
temporary Western population(14). Children who originated in
the lowest and highest birth-weight quintiles had signiﬁcantly
greater odds of being classiﬁed at high metabolic risk by mid-
dle childhood compared with those in the middle nadir birth-
weight quintile.
Although data-driven cluster analysis can be used within a
speciﬁed population, it does not necessarily deﬁne cut-offs
that can be translated to another population. For cross-cohort
comparisons, a consensus deﬁnition based on cut-offs is still
required. As such, there remains a need for expert committees
to deﬁne consensus statements.
Currently there is insufﬁcient longitudinal data to know
what cut-offs predict future disease. Nevertheless, despite
the varying deﬁnitions, overall stability of risk factor clustering
is seen from childhood into adult life(50). Therefore, clustering
of risk factors in childhood is predictive of risk of develop-
ment of the metabolic syndrome in subsequent adult life
Other cardiovascular risk markers in children
Detecting risk of CVD in children, before the expression of
overt cardiovascular endpoints, has been achieved via other
methods. These methods include assessments of vascular
structure and function, inﬂammatory and epigenetic biomar-
kers, non-alcoholic fatty liver disease (NAFLD) and the retinal
vasculature. In making a decision about which of these diverse
methods are best employed in any particular study, two factors
should be considered. The ﬁrst is that methods may potentially
target different pathways in the evolution and the eventual
development of CVD. Ideally the technique(s) chosen should
link to the research question being asked. The second consid-
eration is a practical one. Some methods are more time inten-
sive, expensive and demanding of greater expertise, and need
to be justiﬁed in terms of the greater burdens placed upon
study participants and resources.
Markers of vascular structure and function
Vascular structure and function can be measured by intima
media thickness (IMT), pulse wave velocity (PWV) and ﬂow-
mediated dilatation (FMD).
Atherosclerosis is present in youth, beginning as deposits of
cholesterol and its esters in the endothelial wall. The
Pathobiological Determinants of Atherosclerosis in Youth
(PDAY) study performed autopsies on 3000 individuals
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aged 15 to 34 years dying of unrelated causes(51,52). Evidence
of atherosclerosis was directly observed even at these relatively
young ages, in the form of fatty streaks and narrowing of cor-
onary vessels. This has driven the development of non-
invasive techniques that can be used to detect evidence of
early atherosclerosis in childhood and later cardiovascular
risk. These are indirect measures of subclinical atherosclerosis
and interpretation of these results in children needs to be
undertaken carefully.
Intima media thickness
One method, established in children, for assessing early mor-
phological changes in the vessel wall is measurement of aortic
and carotid IMT. This technique has conﬁrmed that traditional
cardiovascular risk factors (such as obesity, diabetes, hyper-
cholesterolaemia and hypertension) in childhood are asso-
ciated with the formation of early atherosclerotic
lesions(53–55). Jarvisalo et al.(53) showed that, at an average
age of 11 years, children with type 1 diabetes and hyperchol-
esterolaemia had higher IMT compared with a control
group. Children with hypertension (at a mean age of 13·9
years) also had signiﬁcantly greater carotid IMT thickness
than unaffected children(54). Finally, overweight children
have been shown to have signiﬁcantly increased carotid
IMT, even for mild to moderate degrees of obesity(55).
Lower maternal energy intake during pregnancy has also
been shown to be associated with increased carotid IMT in
9-year-old children(56).
Arterial stiffness
Arterial compliance or stiffness is another non-invasive meas-
ure of later cardiovascular risk. Three non-invasive methods of
measuring arterial stiffness are used: (1) measuring PWV; (2)
relating change in diameter (or area) of an artery to distending
ﬂow; and (3) assessing arterial pressure waveforms. Using
these measures, cardiovascular risk can be objectively and
non-invasively quantiﬁed using applanation tonometry
(Sphygmocor) which measures arterial stiffness. Measures of
PWV and augmentation index predict cardiovascular events
and mortality independent of other traditional risk factors in
adults. Increased arterial stiffness has been found in high-risk
groups of children such as those with obesity(57), type 2 dia-
betes(58) and familial hypercholesterolaemia(59). In the Raine
study, we have seen that the high ‘metabolic risk cluster’ par-
ticipants have higher PWV in both sexes. In males, those in
the higher metabolic cluster had higher augmentation index
(derived from the arterial pressure waveform) in males, but
not in females(60).
Fig. 2. 95% CI for parameters related to high-risk cluster at age 8 years. Most of the 95% CI are very divergent and do not overlap. The x axis shows those in high-
and low-risk clusters(14). BP, blood pressure.
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Methods of FMD and PWV measure dynamic changes in
the vasculature. Therefore, experimental conditions need to
be controlled for effects such as exposure to cigarette smoke
and for menstrual cycle phase for adolescent girls. Notably,
IMT measures a structural change and is not sensitive to
these immediate inﬂuences.
Inflammatory and epigenetic biomarkers
C-reactive protein (CRP) is the most studied of the inﬂamma-
tory markers in relation to cardiovascular risk. It is a non-
speciﬁc measure of systemic inﬂammation, and adult studies
show that elevated CRP is associated with an increased risk
of subsequent cardiovascular risk and all-cause mortality(61,62).
This has also been seen in children, which shows that elevated
CRP levels are associated with increased metabolic risk(63),
arterial changes in healthy children(64) and eventual CVD(65).
Mendelian randomisation approaches suggest that these asso-
ciations may not be causal(66).
Adipokines are cytokines produced by adipose tissue and
might provide a mechanistic link between obesity and CVD.
Adipokines include adiponectin and leptin. Plasma leptin con-
centrations correlate with body fat and BMI and may play a
role in the aetiology of hyperinsulinaemia and the insulin
resistance syndrome(67). In adolescents, plasma leptin has
been associated with insulin resistance(68).
Other circulating cytokines associated with cardiovascular
risk in childhood and adolescence include IL-18, soluble
TNF receptors (TNFR) and interferon-γ. In adults, high levels
of plasma IL-18 are associated with central obesity(69), the
metabolic syndrome(70,71) and CVD(72). In adolescents, IL-18
has been associated with BMI and insulin resistance(73).
The effects of TNF-α are mediated by two speciﬁc recep-
tors, a 55 kDa protein (TNFR1) and a 75 kDa protein
(TNFR2)(74). Soluble forms of both receptors are detectable
in plasma and have been used as proxies for TNF-α activ-
ity(75). Elevated plasma levels of TNFR have been associated
with childhood obesity(76,77) and cardiovascular events(78,79).
Interferon-γ-induced protein of 10 kDa (IP-10) is a
pro-inﬂammatory chemokine generated by monocytes to pro-
mote the recruitment of lymphocytes and monocytes to sites
of inﬂammation. It is expressed in human atherosclerotic pla-
ques(80) and plasma levels have been correlated with waist cir-
cumference and BMI in adolescents(73).
Recent studies suggest that epigenetic marks in proxy tissues
may reﬂect mechanistic pathways linking the early environ-
ment with later adiposity and differential risk of CVD(81,82).
As yet there are few data for more direct measures of cardio-
vascular risk, but it is of note that there is now evidence that
some differentially methylated CpG sites are temporally stable
between the ages of 5–7 and 14 years(82).
Non-alcoholic fatty liver disease
As discussed above, obesity is a spectrum from isolated over-
weight to the full cluster of co-morbidities, but typically seen in
the metabolic syndrome. Similarly, the metabolic syndrome is
also associated with other conditions such as NAFLD, the
most prevalent chronic liver condition worldwide. The devel-
opment of NAFLD is associated with key components of the
metabolic syndrome. Individuals with NAFLD typically have
greater levels of BMI Z score, waist circumference, HOMA
and systolic blood pressure(83). An evolving area of interest
is that of the microbiome. The effects of diet on metabolic
liver disease may be mediated, at least in part, by the micro-
biome(84). Ongoing and future mother–birth cohort studies
will be analysing the microbiome at different time points.
Population studies that are large scale and performed on
healthy participants will have ethical constraints for obtaining
‘gold standard’ liver histology by liver biopsy. Therefore, non-
invasive methods for assessing NAFLD are utilised, and MRI
is now accepted as producing reliable assessments of liver fat.
Many population studies have used liver ultrasound.
Assessment by ultrasound may potentially introduce false
negatives, but is feasible in population studies(60,85).
Conclusion
Assessing cardiometabolic risk in children is important in
understanding developmental programming and how these
pathways may be addressed for disease prevention. These car-
diometabolic risk factors can either be predictors or outcomes
in analyses. Current data suggest that early measures of cardi-
ometabolic risk do track into adulthood and predict cardiovas-
cular outcomes. When assessing the role of adiposity in
children, longitudinal statistical techniques and measures of
body composition are likely to be useful. Data-driven techni-
ques, such as cluster analysis, should be considered when
assessing the metabolic risk markers in children. The develop-
ment of more sophisticated cardiovascular risk markers in chil-
dren is constantly evolving. It is important that there is
considered use of these techniques in the context of the patho-
genic pathways being examined. These approaches will add
valuable knowledge to the expanding frontier of developmen-
tal medicine (DOHaD), which is ultimately the most logical
target for preventing disease and curtailing the rising burden
of CVD and other non-communicable disorders.
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